Press Releases

• May 29, 2025

  Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases

• Navigator Medicines at the 2025 AAD Annual Conference

• Mar 5, 2025

  Navigator Medicines to Present Data at the American Academy of Dermatology (AAD) Annual Meeting

• Feb 11, 2025

  Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors

• Aug 27, 2024

  Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases